MetaVia reports dose-dependent weight loss and no CV effects in Phase 1 MAD study of DA-1726

MetaVia Inc.

Clear dose-dependent body weight reduction from 8 mg to 32 mg; BMI change significantly greater vs placebo.
No drug-induced heart rate or QTcF increases up to 32 mg at 4 weeks; mean HR decreased in most cohorts.
Previously reported: max weight loss -6.3% and mean -4.3% at Day 26 for 32 mg; fasted glucose lowered -18 mg/dL.
Additional cohorts to determine maximum tolerated dose; 32 mg likely starting dose for future trials.
All pre-funded warrants exercised for 1,430,000 shares post-announcement; no warrants outstanding.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.